Cue Biopharma Inc.

AI Score

0

Unlock

1.31
0.03 (2.34%)
At close: Feb 10, 2025, 3:59 PM
1.33
1.53%
After-hours Feb 10, 2025, 07:01 PM EST
undefined%
Bid 1.25
Market Cap 82.99M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.91
PE Ratio (ttm) -1.44
Forward PE n/a
Analyst Buy
Ask 1.33
Volume 108,974
Avg. Volume (20D) 416,068
Open 1.25
Previous Close 1.28
Day's Range 1.25 - 1.33
52-Week Range 0.45 - 2.58
Beta undefined

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-10...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2018
Employees 53
Stock Exchange NASDAQ
Ticker Symbol CUE

Analyst Forecast

According to 5 analyst ratings, the average rating for CUE stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 205.34% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Cue Biopharma Inc. is scheduled to release its earnings on Mar 10, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-16.67%
Cue Biopharma shares are trading lower. The compan... Unlock content with Pro Subscription
4 months ago
+49.61%
Cue Biopharma shares are trading higher. The company annonunced it priced its $12 million public offering.